Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2509-4254
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada ; day:26 ; month:4 ; year:2022 ; pages:1-19
PharmacoEconomics - open ; (26.4.2022), 1-19
- Creator
-
Fenu, Elisabetta
Lukyanov, Vasily
Acs, Annabel
Radu, Xenia
Stypa, Stephanie
Fischer, Aren
Marshall, John K.
Oppe, Mark
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s41669-022-00331-9
- URN
-
urn:nbn:de:101:1-2022070909321544503705
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Fenu, Elisabetta
- Lukyanov, Vasily
- Acs, Annabel
- Radu, Xenia
- Stypa, Stephanie
- Fischer, Aren
- Marshall, John K.
- Oppe, Mark
- SpringerLink (Online service)
Other Objects (12)
Identifying predictive signalling networks for Vedolizumab response in ulcerative colitis
Vedolizumab Treatment for Ulcerative Colitis in an Elderly Multimorbid Patient with Hemophilia A
Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab
Association of CD4-positive cell infiltration with response to vedolizumab in patients with ulcerative colitis
Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials
Comparative Efficacy and Safety of Upadacitinib vs. Vedolizumab, Ustekinumab, and Tofacitinib After Induction and Maintenance for Ulcerative Colitis: Three Matching-Adjusted Indirect Comparisons
Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles
Ulcerative colitis successfully treated with vedolizumab in the presence of comorbid opportunistic infections: a case report
Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn’s Disease Patients Stratified by Age
Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study
Ulcerative colitis - Crohn's disease
Ulcerative Colitis: Shifting Sands
Identifying predictive signalling networks for Vedolizumab response in ulcerative colitis
Vedolizumab Treatment for Ulcerative Colitis in an Elderly Multimorbid Patient with Hemophilia A
Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab
Association of CD4-positive cell infiltration with response to vedolizumab in patients with ulcerative colitis
Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials
Comparative Efficacy and Safety of Upadacitinib vs. Vedolizumab, Ustekinumab, and Tofacitinib After Induction and Maintenance for Ulcerative Colitis: Three Matching-Adjusted Indirect Comparisons
Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles
Ulcerative colitis successfully treated with vedolizumab in the presence of comorbid opportunistic infections: a case report
Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn’s Disease Patients Stratified by Age
Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study
Ulcerative colitis - Crohn's disease
Ulcerative Colitis: Shifting Sands
Identifying predictive signalling networks for Vedolizumab response in ulcerative colitis
Vedolizumab Treatment for Ulcerative Colitis in an Elderly Multimorbid Patient with Hemophilia A
Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab
Association of CD4-positive cell infiltration with response to vedolizumab in patients with ulcerative colitis
Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials
Comparative Efficacy and Safety of Upadacitinib vs. Vedolizumab, Ustekinumab, and Tofacitinib After Induction and Maintenance for Ulcerative Colitis: Three Matching-Adjusted Indirect Comparisons
Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles
Ulcerative colitis successfully treated with vedolizumab in the presence of comorbid opportunistic infections: a case report
Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn’s Disease Patients Stratified by Age
Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study
Ulcerative colitis - Crohn's disease